NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kriya Therapeutics

Kriya Therapeutics

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://kriyatherapeutics.com/

Last Round

Series D

Sep 10, 2025

Total Funding Raised

$1.08B

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Kriya Therapeutics is a biotechnology company that designs and develops gene therapies for chronic diseases affecting large patient populations.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

gene therapyviral vectorbiotechgenetic medicineAAVadeno-associated virusbiomanufacturingGMP manufacturingdrug discoverymetabolic diseaseophthalmologyvector engineeringprecision medicinebiotech startuptherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kriya Therapeutics Comparables

Compare Kriya Therapeutics with similar companies based on industry and business-model similarity.

Kriya Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ring Therapeutics
82%
4DMT
81%
Frontera Therapeutics
81%

Kriya Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 10, 2025
Series C ExtensionJul 26, 2023
Series CMay 16, 2022
Series BJul 14, 2021
Series AMay 12, 2020
Seed
Oct 1, 2019

Key People

Founding team and executive leadership

J Fraser Wright

Chief Gene Therapy Officer, Scientific Co-Founder

Founding Team

Shankar Ramaswamy

Co-Founder and Chief Executive Officer

Founding Team

Curt Herberts

President Chief Operating Officer

Executive Team

Mark Chen

Chief Operating Officer

Executive Team

Kriya Therapeutics Investors

Notable investors and investment history

Kriya Therapeutics investors
InvestorRounds
Narya CapitalSeries C, Series B, Series A, Series D
CAM CapitalSeries C, Series B
AmploSeries B, Series A
Patient Square CapitalSeries C, Series C Extension, Series B, Series D
Hongkou CapitalSeries B
Foresite CapitalSeries C, Series B, Series A
PBM Capital GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 4, 2026

    Hiring business owner for Dot Compliance eQMS platform.

  • Sep 10, 2025

    $320M Series D round completed.

Kriya Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kriya Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kriya Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range199
Year Founded2019
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.